QA1.71

Lynch syndrome

Filed alongside this entry 3

under Susceptibility to disease, genetic

Index entries, exactly as the book files them. This says they are listed together — not that any of them is documented in your chart.

Billable FY2027 2026-10-01 → 2027-09-30 FY2027–2027 only

How to use this page

Everything the published sources say about one code, on one page.

Read the Excludes1 block first — it is the one that stops you coding this at all alongside another code.
Excludes2, Code first, Use additional and Includes follow. A note inherited from a parent category is labelled with the category it came from, so you can see why it applies.
Official Guidelines sit below. "Guidelines naming this code" cite the code or a range containing it; "Chapter guidance" is the general guidance for its chapter and is the weaker signal.
Guideline text is quoted verbatim with its section number and page, so you can check it against the published document.
Risk-model chips show which published CMS models map this code.

What this page does not do

Guidance is quoted, never paraphrased — a paraphrase of a coding rule is a different rule.
Medication candidates, where shown, are matched by condition *name* and are offered as candidates for you to judge. They are not "the drugs for this code".

Exclusions1never code together

QA1code

Excludes2

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes10

QA1code

Code also

Inclusion terms

Official Guidelines

No guideline section names this code or its chapter.

Index entries leading here2

Susceptibility to disease, genetic Z15.89
- hereditary nonpolyposis colorectal cancer QA1.71
Syndrome — see also Disease
- Lynch (due to EPCAM) (due to MLH1) (due to MSH2) (due to MSH6) (due to PMS2) QA1.71

Alongside this code1same parent — QA1.7

Additional references

AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.